Bayer Wins FDA Approval For Hyrnuo As Second Drug For HER2-Mutant NSCLC

 
• By Alaric DeArment
  
The FDA gave accelerated approval to Bayer's Hyrnuo in HER2-mutant NSCLC. (Shutterstock)

More from New Products

More from Scrip